CompletedNot Applicable

Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

China80 participantsStarted 2017-02-14

Plain-language summary

To investigate the efficacy of laser photocoagulation combined with ranibizumab intravitreal injection in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in long term.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent
✓. Male or female Chinese patients ≥ 18 years of age with BRVO
✓. Visual impairment due to ME secondary to BRVO in at least one eye with BCVA score between 73 and 24 and at least 24 letters in the other eye

Exclusion criteria

✕. Pregnant or nursing (lactating) women or women of child-bearing potential without using effective contraception
✕. Stroke or myocardial infarction less than 3 months prior to screening visit
✕. Renal failure or creatinine levels \> 2.0 mg/dl
✕. Uncontrolled hypertension
✕. Active ocular infection or intraocular inflammation in any eye
✕. Neovascularization of the iris or neovascular glaucoma in any eye
✕. History of uveitis or vitreomacular traction in any eye
✕. Treatment with any anti-angiogenic drugs within 3 months prior to baseline visit in any eye

What they're measuring

visual acuity changes

Timeframe: one year

Trial details

NCT IDNCT03054766

SponsorBeijing Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2018-02-01

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion trials